Primary Series Hospitalization/Severe Disease ■ non-mRNA ■ Multiple mRNA Study Country Design VE (95% CI) С 0.95 (0.92, 0.97) Bar-On et al. (5) Israel MC Barda et al. (63) Israel 0.93 (0.88, 0.97) Muhsen et al. (69) С 0.93 (0.85, 0.97) Israel USA MC Sharma et al. (71) 0.45 (0.27, 0.58) Mattiuzzi and Lippi (37) Italy С 0.69 (0.56, 0.78) 0.82 (0.56, 0.94) McConeghy et al. (57) (S1) USA С С USA 0.46 (-0.16, 0.79) McConeghy et al. (57) (S2) USA MC 0.81 (0.80, 0.82) Mehta et al. (82) С USA 0.70 (0.48, 0.83) Tartof et al. (19) USA MC Butt et al. (20) 0.52 (0.46, 0.57) UK MC Hulme et al. (75) 0.80 (0.78, 0.82) 0.96 (0.88, 1.00) Andersson et al. (17) **Finland** MC MC 0.88 (0.71, 1.00) Andersson et al. (17) Norway Andersson et al. (17) MC 0.90 (0.80, 1.00) Sweden Sweden MC 0.88 (0.81, 0.95) Andersson et al. (17) USA MC \vdash 0.53 (0.48, 0.58) Ioannou et al. (41) С Ng et al. (76) Singapore 0.70 (0.49, 0.82) С Kislaya et al. (32) (60-79yo) Portugal 0.21 (0.02, 0.36) С Portugal Kislaya et al. (32) (80+yo) 0.16 (0.01, 0.28) Ridgway et al. (29) USA MCC \vdash 0.59 (0.54, 0.63) USA MC Desai et al. (18) 0.44 (0.02, 0.68) Chemaitelly et al. (78) MC 0.80 (0.56, 0.91) Qatar -0.250 0.25 0.5 0.75 1 Vaccine Effectiveness (VE)

Mortality

